• Mashup Score: 0

    Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…

    Tweet Tweets with this article
    • PSMA-PET implications for extent and survival outcomes in high-risk #nmCRPC: an international study. @ProfHadaschik @unidue joins @CaPsurvivorship @DanaFarber for an insightfull discussion on UroToday > https://t.co/vtWfw0mtuj https://t.co/KxTBthHxgM

  • Mashup Score: 0

    Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.

    Tweet Tweets with this article
    • Alicia K. Morgans, MD, MPH, discusses real-world evidence showing patients with #nmcrpc on darolutamide have a longer time to discontinuation vs enzalutamide and apalutamide. #pcsm | @DanaFarber @CaPsurvivorship @DanaFarber_GU https://t.co/LaDky8YXHI

  • Mashup Score: 2

    Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik’s presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik…

    Tweet Tweets with this article
    • PSMA-PET implications for extent and survival outcomes in high-risk #nmCRPC: an international study. @ProfHadaschik @unidue joins @CaPsurvivorship @DanaFarber for an insightfull discussion on UroToday > https://t.co/vtWfw0mtuj https://t.co/ex0WneOsoz